MA31714B1 - Derive de pyrazole substitue - Google Patents

Derive de pyrazole substitue

Info

Publication number
MA31714B1
MA31714B1 MA32720A MA32720A MA31714B1 MA 31714 B1 MA31714 B1 MA 31714B1 MA 32720 A MA32720 A MA 32720A MA 32720 A MA32720 A MA 32720A MA 31714 B1 MA31714 B1 MA 31714B1
Authority
MA
Morocco
Prior art keywords
group
atom serving
bonding agent
serving
pyrazole derivative
Prior art date
Application number
MA32720A
Other languages
Arabic (ar)
English (en)
Inventor
Mitsuhiro Ito
Tomohiko Suzaki
Satoshi Yamamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA31714B1 publication Critical patent/MA31714B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne un dérivé inédit du pyrazole et un antagoniste du récepteur aux androgènes contenant ledit dérivé de pyrazole. L'invention concerne, plus précisément, un composé de formule (i') ci-dessous ou un sel de celle-ci. (dans la formule, r1 représente un atome d'hydrogène, un groupe comportant un atome de carbone servant d'agent de liaison, un groupe comportant un atome d'azote servant d'agent de liaison, un groupe comportant un atome d'oxygène servant d'agent de liaison ou un groupe comportant un atome de soufre servant d'agent de liaison; r2 représente un groupe phényle comportant un groupe cyano (et qui peut, en outre, comporter un substituant autre qu'un groupe cyano); r3 représente un atome d'hydrogène, un groupe comportant un atome de carbone servant d'agent de liaison, un groupe comportant un atome d'azote servant d'agent de liaison, un groupe comportant un atome d'oxygène servant d'agent de liaison ou un groupe comportant un atome de soufre servant d'agent de liaison; r4 représente un groupe cyclique éventuellement substitué; et x représente un groupe co ou méthylène éventuellement substitué.
MA32720A 2007-08-30 2010-03-26 Derive de pyrazole substitue MA31714B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007224910 2007-08-30
PCT/JP2008/065286 WO2009028543A1 (fr) 2007-08-30 2008-08-27 Dérivé de pyrazole substitué

Publications (1)

Publication Number Publication Date
MA31714B1 true MA31714B1 (fr) 2010-09-01

Family

ID=40387261

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32720A MA31714B1 (fr) 2007-08-30 2010-03-26 Derive de pyrazole substitue

Country Status (20)

Country Link
US (2) US20100227846A1 (fr)
EP (1) EP2194045A4 (fr)
JP (1) JPWO2009028543A1 (fr)
KR (1) KR20100046275A (fr)
CN (1) CN101842357A (fr)
AR (1) AR068813A1 (fr)
AU (1) AU2008292429A1 (fr)
BR (1) BRPI0816095A2 (fr)
CA (1) CA2697663A1 (fr)
CL (1) CL2008002521A1 (fr)
CO (1) CO6190530A2 (fr)
DO (1) DOP2010000068A (fr)
EA (1) EA201070323A1 (fr)
EC (1) ECSP10010060A (fr)
MA (1) MA31714B1 (fr)
MX (1) MX2010002266A (fr)
PE (1) PE20090610A1 (fr)
TN (1) TN2010000091A1 (fr)
TW (1) TW200913993A (fr)
WO (1) WO2009028543A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2720343A1 (fr) * 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Derive heterocyclique et son utilisation
WO2011029782A1 (fr) * 2009-09-11 2011-03-17 Bayer Schering Pharma Aktiengesellschaft Thiohydantoïnes à substitution hétéroarylméthyle, en tant que médicaments anticancer
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
WO2012054367A1 (fr) 2010-10-19 2012-04-26 Boehringer Ingelheim International Gmbh Inhibiteurs des rho-kinases
EA201390598A1 (ru) 2010-10-22 2013-08-30 Астеллас Фарма Инк. Антагонист мутантного андрогенного рецептора
AU2012232670A1 (en) 2011-03-23 2013-09-12 Ariel-University Research And Development Company Ltd. Treatment of proliferative disorders with a chemiluminescent agent
WO2012143599A1 (fr) * 2011-04-21 2012-10-26 Orion Corporation Carboxamides modulant les récepteurs d'androgènes
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
JP6057698B2 (ja) * 2012-12-25 2017-01-11 東レ・ダウコーニング株式会社 イミド基含有有機ケイ素化合物の製造方法
US10155727B2 (en) 2014-08-15 2018-12-18 Janssen Pharmaceuticals, Inc. Pyrazoles
WO2016025917A1 (fr) 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles à titre d'inhibiteurs des récepteurs nr2b
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
AU2016291158B2 (en) 2015-07-09 2020-04-30 Janssen Pharmaceutica Nv Substituted 4-azaindoles and their use as GluN2B receptor modulators
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
US10071988B2 (en) 2016-02-10 2018-09-11 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CN109310664A (zh) * 2016-06-10 2019-02-05 田纳西大学研究基金会 选择性雄激素受体降解剂(sard)配体和其使用方法
US10806719B2 (en) 2016-06-10 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
WO2018195155A1 (fr) * 2017-04-18 2018-10-25 Celgene Quanticel Research, Inc. Composés thérapeutiques
CN107903213A (zh) * 2017-09-28 2018-04-13 山东大学 5‑甲基‑1h‑吡唑衍生物及其制备方法和应用
WO2019193516A2 (fr) 2018-04-04 2019-10-10 Janssen Pharmaceutica Nv Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b
CN108676001A (zh) * 2018-06-12 2018-10-19 江西师范大学 一种3-取代-5-异噁唑基-4-取代-1-1,2,3-三氮唑基甲烷化合物
WO2020051344A1 (fr) 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Ligands de composés de dégradation sélectifs de récepteurs des androgènes (sard) et procédés d'utilisation associés
MX2021015511A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de pirazina y sus usos como moduladores del receptor glun2b.
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピラゾロ-ピリジンアミド及びglun2b受容体調節因子としてのその使用
TW202112774A (zh) 2019-06-14 2021-04-01 比利時商健生藥品公司 經取代之吡唑并-吡啶醯胺及其作為glun2b受體調節劑之用途
CN114008052A (zh) 2019-06-14 2022-02-01 詹森药业有限公司 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途
BR112021025141A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b
AU2020293642A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
CA3143103A1 (fr) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Carbamates de pyridine et leur utilisation en tant que modulateurs du recepteur glun2b
JP7288665B2 (ja) * 2019-08-02 2023-06-08 株式会社デ・ウエスタン・セラピテクス研究所 エチルアニリノトルエンスルホン酸誘導体の製造方法
CN111499539B (zh) * 2020-04-20 2022-10-11 南昌大学 一种以芳基羧酸为原料的芳基氰化物合成方法
BR112023002159A2 (pt) * 2020-08-04 2023-04-25 Prec Bio Therapeutics S R L Composto, uso do composto e composição famacêutica
CN119451953A (zh) * 2022-07-15 2025-02-14 株式会社 钟根堂 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑三唑化合物和包含其的药物组合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US401275A (en) * 1889-04-09 Wagon-tire
AU7553198A (en) * 1997-06-12 1998-12-30 Sumitomo Pharmaceuticals Company, Limited Pyrazole derivatives
US20040229900A1 (en) * 1999-06-16 2004-11-18 Astrazeneca Ab Bispidine compounds useful in the treatment of cardiac arrythmias
SE0002603D0 (sv) * 2000-07-07 2000-07-07 Astrazeneca Ab New compounds
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
JP4303109B2 (ja) * 2001-10-04 2009-07-29 メルク エンド カムパニー インコーポレーテッド 代謝共役型グルタミン酸受容体−5のヘテロアリール置換テトラゾール調節剤
DE60223720T2 (de) * 2001-12-18 2008-10-30 Merck & Co., Inc. Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5
DE60222698T2 (de) * 2001-12-18 2008-06-19 Merck & Co., Inc. Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5
WO2003053922A2 (fr) * 2001-12-19 2003-07-03 Merck & Co., Inc. Imidazoles substitues par heteroaryle modulateurs du recepteur metabotropique du glutamate de type 5
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1458710A4 (fr) * 2001-12-21 2005-04-20 Merck & Co Inc Modulateurs pyrrole a substitution heteroaryle du recepteur 5 metabotropique du glutamate
EP1465869B1 (fr) * 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulateurs de lxr
AU2002367424A1 (en) * 2001-12-28 2003-07-24 Takeda Chemical Industries, Ltd. Androgen receptor antagonists
AU2003216581A1 (en) * 2002-04-12 2003-10-27 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
US20040142978A1 (en) * 2002-12-12 2004-07-22 Pharmacia Corporation Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
US20040127519A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
US20040127511A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
CA2565211A1 (fr) * 2004-04-29 2005-11-24 Abbott Laboratories Analogues d'amino-tetrazoles et methodes d'utilisation
US7880001B2 (en) * 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
TW200628446A (en) * 2004-12-14 2006-08-16 Takeda Pharmaceuticals Co Substituted pyrrole derivative
BRPI0710527B8 (pt) * 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
JP2007332053A (ja) * 2006-06-13 2007-12-27 Takeda Chem Ind Ltd 置換ピロール誘導体
MX2009013213A (es) * 2007-06-08 2010-03-30 Abbott Lab Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa.
PE20091653A1 (es) * 2008-03-26 2009-11-14 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso

Also Published As

Publication number Publication date
WO2009028543A1 (fr) 2009-03-05
KR20100046275A (ko) 2010-05-06
EP2194045A1 (fr) 2010-06-09
EP2194045A4 (fr) 2011-09-21
BRPI0816095A2 (pt) 2015-03-03
CA2697663A1 (fr) 2009-03-05
US20100227846A1 (en) 2010-09-09
CO6190530A2 (es) 2010-08-19
TN2010000091A1 (en) 2011-09-26
US20090270359A1 (en) 2009-10-29
MX2010002266A (es) 2010-03-25
DOP2010000068A (es) 2010-03-15
CN101842357A (zh) 2010-09-22
JPWO2009028543A1 (ja) 2010-12-02
CL2008002521A1 (es) 2009-11-20
PE20090610A1 (es) 2009-06-11
EA201070323A1 (ru) 2010-10-29
AU2008292429A1 (en) 2009-03-05
ECSP10010060A (es) 2010-04-30
AR068813A1 (es) 2009-12-09
TW200913993A (en) 2009-04-01

Similar Documents

Publication Publication Date Title
MA31714B1 (fr) Derive de pyrazole substitue
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
SG162805A1 (en) Pyrazine derivatives useful as adenosine receptor antagonists
MXPA05009059A (es) Derivados de heteroarilcarbamoilbenceno.
MA33851B1 (fr) Compose heterocyclique contenant de l'azote et fongicide agricole
WO2008108378A3 (fr) Dérivé bicyclique d'oxomorpholine
MX2009010814A (es) Compuestos de hidrazida y agente controlador de artropodos dañinos que contiene el mismo.
TW200510381A (en) Novel 2-pyridinecarboxamide derivatives
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
MX2009010024A (es) Nuevo compuesto de adenina.
WO2009057784A1 (fr) Composé hétérocyclique
NO20062633L (no) Pyrazolderivater som proteinkinasemodulatorer
MY150630A (en) Amide derivative and insecticide containing the same
ES2571327T3 (es) Composiciones plaguicidas
MXPA05012033A (es) Compuesto de pirimidina y composicion para el control de plagas que contiene el mismo.
PA8797301A1 (es) Derivados de nicotinamida, su preparacion y su aplicacion en terapeutica
PE20071232A1 (es) Derivados de piperidina o piperazina como inhibidores de 11-beta hsd1
MX2009010823A (es) Compuesto de hidrazida y agente controlador de artropodos dañinos que contiene el mismo.
TW200745034A (en) New compounds
MY150269A (en) Novel phenylpyrrole derivative
NO20064200L (no) Fremgangsmate for syntese av en CXCR4-antagonist
DK1961734T3 (da) Aminforbindelse og anvendelse deraf til medicinske formål
NO20085317L (no) Imidazoazepinonforbindelser
EA200601279A1 (ru) Пиперидинилкарбонилпирролидины и их применение в качестве агонистов меланокортина
NO20080165L (no) Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister